In general, there are several different RNA therapeutic approaches including mRNAs, antisense oligonucleotides (ASOs), siRNAs and miRNAs. miRNA mimics are small double-stranded RNA molecules that associate with and guide the RISC complex to its target mRNA. miRNA inhibitors are small single-stranded RNAs that bind to and suppress their target miRNA, and this results in restored mRNA translation. NEORNAT’s first pipeline, NRT-YHD, is a modified miRNA inhibitor. NEORNAT has discovered novel miRNA which suppresses macrophage phagocytic activation toward cancer cells. NRT-YHD is modified anti-sense miRNA that functions as novel macrophage immune-check point inhibitor.
siRNAs are small double-stranded RNA molecules that have exact complementarity to a target mRNA. Once associated with the RISC complex, it binds to its target mRNA and induces gene silencing by preventing translation of the mRNA. NRT-FX pipeline is double siRNA therapy that target both long non-coding RNA and subunit of SWI/SNF complexes. NEORNAT have demonstrated that these two molecules simultaneously contribute to cancer development and progression. Therefore, it is unique strategy to regulate coding & non-coding RNA for the development of RNA therapeutics in cancer.
NRT-NMJ pipeline targets novel DNA repair enzyme for cancer treatment. NEORNAT has identified specific DNA repair enzymes which aberrantly deregulated in cancers. Targeting single or combination of these DNA repair enzymes showed strong anti-caner effects in vitro and in vivo.

• NRT-YHD

  Macrophage immune-check point inhibitor

  

• NRT-FX

  Macrophage-mediated clearance of necroptotic hepatocytes and anti-fibrotic therapeutic

  

• NRT-NMJ

  DNA mismatch repair enzyme inhibitor